Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 180.60B |
| Revenue (ttm) | 42.26B |
| Net Income (ttm) | 13.89B |
| Shares Out | n/a |
| EPS (ttm) | 3.12 |
| PE Ratio | 13.00 |
| Forward PE | 12.26 |
| Dividend | 1.56 (3.77%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 349,665 |
| Average Volume | 303,853 |
| Open | 41.58 |
| Previous Close | 41.43 |
| Day's Range | 40.47 - 41.69 |
| 52-Week Range | 35.76 - 90.46 |
| Beta | 0.35 |
| RSI | 44.16 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
FDA approves first GLP-1 pill for obesity from Novo Nordisk
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Novo Nordisk wins US approval for weight-loss pill
The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it ...
These 5 Stocks Are Set To Dominate 2026
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Euro...
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Novo Nordisk: Oral Wegovy, Supply Chain, And Restructuring = Big Upside Ahead
Novo Nordisk offers compelling value, trading at a 32% discount to fair value with a 3.6% yield and robust dividend growth. NVO's semaglutide-based drugs drive 74% of sales, but pipeline innovation, c...
Prediction: 1 Healthcare Giant Set to Soar in 2026
Novo Nordisk cut its guidance and changed its CEO this past year. Amid the troubling developments, the stock has nose-dived more than 40%.
Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
Better Buy in 2026: Novo Nordisk or Intuitive Surgical?
Novo Nordisk's new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in its niche despite increased competition.
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk
These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year.
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
Novo Nordisk A/S (NYSE: NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
2 Predictions for Novo Nordisk in 2026
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026.
EU drugs regulator backs higher dose of Novo's Wegovy
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut.
Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.
Novo Nordisk brings Ozempic to India as weight-loss demand accelerates
Novo Nordisk has officially launched Ozempic in India, marking a significant expansion of its presence in one of the world's fastest-growing markets for diabetes and obesity treatments. The launch com...
Novo Nordisk launches blockbuster diabetes drug Ozempic in India
Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday.
Why Novo Nordisk Stock Topped the Market on Thursday
A bipartisan bill has been introduced in the U.S. Congress that would curb some activities of compound pharmacies. The maker of Wegovy has been particularly affected by competition from such parties.
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on...
3 Absurdly Cheap Stocks That Look Like Steals Right Now
UPS, Novo Nordisk, and Adobe are all trading well below the S&P 500's average price-to-earnings ratio. Their underlying businesses are solid and profitable.
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap de...
Why Novo Nordisk Stock Was Melting on Monday
The Wegovy and Ozempic maker was hit with an analyst recommendation downgrade. A onetime bull now feels the stock is only a hold.
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests.